HC Wainwright Has Bullish Forecast for GLUE FY2026 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Monte Rosa Therapeutics in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($1.30) per share for the year, up from their prior estimate of ($1.81). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics’ Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.23) EPS.

GLUE has been the subject of a number of other reports. Wells Fargo & Company lowered their target price on Monte Rosa Therapeutics from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday, November 4th. Wall Street Zen raised shares of Monte Rosa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Raymond James Financial set a $25.00 price objective on shares of Monte Rosa Therapeutics in a research report on Monday, October 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.44.

View Our Latest Analysis on Monte Rosa Therapeutics

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $10.31 on Tuesday. The company has a market cap of $880.99 million, a price-to-earnings ratio of -7.36 and a beta of 1.40. Monte Rosa Therapeutics has a 1 year low of $9.68 and a 1 year high of $25.77. The stock’s 50 day simple moving average is $11.50 and its two-hundred day simple moving average is $16.90.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.24. Monte Rosa Therapeutics had a negative return on equity of 30.14% and a negative net margin of 186.24%. The business had revenue of $54.37 million during the quarter, compared to analysts’ expectations of $33.87 million.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several institutional investors have recently modified their holdings of the stock. Allworth Financial LP purchased a new position in shares of Monte Rosa Therapeutics in the 2nd quarter worth approximately $30,000. Sterling Capital Management LLC increased its position in shares of Monte Rosa Therapeutics by 842.3% during the 3rd quarter. Sterling Capital Management LLC now owns 2,450 shares of the company’s stock valued at $29,000 after purchasing an additional 2,190 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Monte Rosa Therapeutics during the 3rd quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Monte Rosa Therapeutics during the 3rd quarter valued at $52,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Monte Rosa Therapeutics during the 2nd quarter valued at $200,000. 79.96% of the stock is owned by institutional investors.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

Read More

Earnings History and Estimates for Monte Rosa Therapeutics (NASDAQ:GLUE)

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.